Publication

Tumor-Targeted Prodrug ICT2588 Demonstrates Therapeutic Activity Against Solid Tumors and Reduced Potential For Cardiovascular Toxicity

Gill, Jason H.
; ; ; 
Cooper, Patricia A.
; 
Atkinson, Jennifer M.
; 
Ribeiro Morais, Goreti
; 
Patterson, Laurence H.
; 
Falconer, Robert A.
Publication Date
18/03/2014
End of Embargo
Supervisor
Keywords
Cancer therapy, Drug delivery, Nanotherapeutic, Peptide conjugate, Matrix metalloproteinase, Vascular disrupting agent
Rights
Peer-Reviewed
Yes
Open Access status
closedAccess
Accepted for publication
07/03/2014
Institution
Department
Awarded
Embargo end date
Collections
Life Sciences Publications
Show all metadata
Additional title
Abstract
Development of therapeutic strategies for tumor-selective delivery of therapeutics through exploitation of the proteolytic tumor phenotype has significant scope for improvement of cancer treatment. ICT2588 is a peptide-conjugated prodrug of the vascular disrupting agent (VDA) azademethylcolchicine developed to be selectively hydrolyzed by matrix metalloproteinase-14 (MMP-14) within the tumor. In this report, we extend our previous proof-of-concept studies and demonstrate the therapeutic potential of this agent against models of human colorectal, lung, breast, and prostate cancer. In all tumor types, ICT2588 was superior to azademethylcolchicine and was greater or comparable to standard clinically used agents for the respective tumor type. Prodrug activation in clinical human lung tumor homogenates relative to stability in human plasma and liver was observed, supporting clinical translation potential. A major limiting factor to the clinical value of VDAs is their inherent cardiovascular toxicity. No increase in plasma von Willebrand factor (vWF) levels, an indicator of systemic vascular dysfunction and acute cardiovascular toxicity, was detected with ICT2588, thereby supporting the tumor-selective activation and reduced potential of ICT2588 to cause cardiovascular toxicity. Our findings reinforce the improved therapeutic index and tumorselective approach offered by ICT2588 and this nanotherapeutic approach.
URI
http://hdl.handle.net/10454/8823
Version
No full-text in the repository
Citation
Gill JH, Loadman Paul M, Shnyder SD et al (2014) Tumor-Targeted Prodrug ICT2588 Demonstrates Therapeutic Activity against Solid Tumors and Reduced Potential for Cardiovascular Toxicity. Molecular Pharmaceutics. 11(4): 1294-1300.
Link to publisher’s version
Link to published version
Link to Version of Record
https://doi.org/10.1021/mp400760b
Type
Article
Qualification name
Notes